Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gynecologic 1Genitourinary 1Gastrointestinal 1Dermatologic 1

Conditions

Melanoma 32Neoplasms 14Carcinoma, Non-Small-Cell Lung 10Colorectal Neoplasms 8Ovarian Neoplasms 7Multiple Myeloma 6Breast Neoplasms 6Pancreatic Neoplasms 5Neoplasm Metastasis 4Hematologic Neoplasms 4Solid Tumors 3Neoplasms by Site 3Lymphoma, Non-Hodgkin 3Lung Neoplasms 3Leukemia, Myeloid, Acute 3Gastrointestinal Neoplasms 3Cholangiocarcinoma 3Brain Neoplasms 3Urinary Bladder Neoplasms 2Thyroid Neoplasms 2Thyroid Carcinoma, Anaplastic 2Thyroid Cancer, Papillary 2Solid Tumor 2Skin Neoplasms 2Sarcoma 2Prostatic Neoplasms 2Neoplasms by Histologic Type 2Leukemia, Myelomonocytic, Chronic 2Gallbladder Neoplasms 2Fallopian Tube Neoplasms 2

Interventions

osimertinib 2sotorasib 1pembrolizumab 1nazartinib 1cobimetinib 1Waiting Lists 1Lovastatin 1Lamotrigine 1Cetuximab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Noonan Syndrome × cobimetinib × Clear all
NCT03989115 2023-06-26

Dose-Esc/Exp RMC4630 & Cobi in Relapsed/Refractory Solid Tumors & RMC4630& Osi in EGFR+ Locally Adv/Meta NSCLC

Revolution Medicines, Inc.

Phase 1/2 Completed
113 enrolled 22 charts
DermatologicGastrointestinalGenitourinaryGynecologicThoracic

Urinary Bladder Neoplasms, Bronchial Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Uterine Cervical Neoplasms, Gastrointestinal Neoplasms, Lung Diseases, Lung Neoplasms, Neoplasms, Neoplasms by Site, Noonan Syndrome, Ovarian Neoplasms, Pancreatic Neoplasms, Respiratory Tract Diseases, Respiratory Tract Neoplasms, Skin Neoplasms, Thoracic Neoplasms, Uterine Neoplasms, Colorectal Neoplasms, Neoplasms, Squamous Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡